Accessibility Menu
Cryo-Cell International logo

Cryo-Cell International(NYSEMKT) CCEL

Market Cap$32.25MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1991)-40%
5 Year-63%
1 Year-11%
1 Month+23%
$4.20
+5.00%
+0.20Today
Cryo-Cell International last closing stock price
MetricPriceDate
Last closeUSD 4.202026-08-31
Cryo-Cell International stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-4.33%USD 4.392026-08-24
1 month+22.81%USD 3.422026-07-31
3 month+23.89%USD 3.392026-06-02
Year to date+22.1%USD 3.442025-12-31
1 year-10.64%USD 4.702025-08-29
3 year-21.95%USD 5.382023-09-01
5 year-62.64%USD 11.242021-09-01
Since inception-39.55%USD 6.621991-01-10

Cryo-Cell International Financials at a Glance

Market Cap

$32.25MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$31.13M

Net Income (TTM)

-$2.47M

EPS (TTM)

-$0.31

P/E Ratio

-13.05

Dividend

$0.00

Beta (Volatility)

0.19 (Low)

Price

$4.20

Volume

10,254.477

Open

$4.00

Previous Close

$4.20

Daily Range

$4.00 - $4.22

52-Week Range

$2.72 - $5.01

Estimated Earnings Date

Oct 9, 2026

CCEL News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cryo-Cell International

Cryo-Cell helps families store newborn stem cells for future medical use. Its services let parents save umbilical cord blood and tissue, which may help treat certain diseases. The company also offers cold storage for healthcare clients.

Products and Services

  • Private Cord Blood and Tissue Banking: Collects and stores newborn stem cells for families (99.5% of revenue in Q1 FY2026).
  • Cord Tissue Service: Preserves umbilical cord tissue, a source of regenerative stem cells, for family use (included in private banking).
  • PrepaCyte CB Processing System: Sells a proprietary system to process cord blood stem cells (0.5% of revenue in Q1 FY2026).
  • Public Cord Blood Banking: Stores donated cord blood for public use and sells units to transplant centers (0.02% of revenue in Q1 FY2026).
  • ExtraVault Cold Storage: Provides secure storage for pharmaceutical and healthcare clients (launched recently, revenue not separately disclosed).
  • International Licensing: Licenses cord blood programs in Central America (revenue not separately disclosed).

Growth and Expansion

  • Launched ExtraVault cold storage services in Durham, North Carolina, in 2025.
  • Signed a license agreement with Duke University in 2021 for biopharma expansion (now in legal dispute).
  • Expanded international licensing to Costa Rica, El Salvador, Guatemala, Honduras, Nicaragua, and Panama (years not specified).
  • Opened a 56,000 sq. ft. facility in Durham, North Carolina, in 2022 for storage and future manufacturing.

What Makes Cryo-Cell Stand Out

Cryo-Cell was the first private cord blood bank to separate and store stem cells. Its facilities meet strict quality standards and use proprietary processing technology. The company offers both private and public banking, plus secure storage for healthcare clients.

Five Things You Need to Know

  • Revenue was $8 million in Q4 2025, down 2.3% from Q4 2024.
  • Net income was -$4 million in Q4 2025, down from -$122,347 in Q4 2024.
  • Operating cash flow was $1 million in Q4 2025, down 40.6% year-over-year.
  • Private cord blood and tissue banking made up 99.5% of Q1 FY2026 revenue.

Bottom Line

Cryo-Cell has evolved from a single-service provider to a diversified storage and processing company. Its focus remains on stem cell banking, with new ventures in healthcare storage and international licensing.

AI Generated • Apr 16, 2026

Industry

Healthcare Providers and Services

Sector

Health Care

Employees

76

CEO

David I. Portnoy; Mark L. Portnoy

Website

www.cryo-cell.com

Headquarters

Oldsmar, FL 34677, US

CCEL Financials

Key Financial Metrics (TTM)

Gross Margin

77.34%

Operating Margin

-0.33%

Net Income Margin

-7.92%

Return on Equity

14.18%

Return on Capital

N/A

Return on Assets

-4.06%

Earnings Yield

-7.66%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$32.25MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

8.06M

Volume

10.25K

Avg. Volume

21.74K

Financials (TTM)

Gross Profit

$24.07M

Operating Income

-$103.78K

EBITDA

$578.36K

Operating Cash Flow

$6.32M

Capital Expenditure

-$205.78K

Free Cash Flow

$6.11M

Cash & ST Invst.

$3.16M

Total Debt

$8.96M

Cryo-Cell International Performance Analysis

Cryo-Cell International annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-11-30USD 30,336,7495.0%
20232023-11-30USD 31,343,6953.3%
20242024-11-30USD 31,986,1062.0%
20252025-11-30USD 31,566,321-1.3%
Cryo-Cell International sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-08-29-1.3%
Q42025-11-300.2%
Q12026-02-28-2.0%
Q22026-05-311.2%
Cryo-Cell International annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-11-30USD 0.3331.1%
20232023-11-30USD -1.14N/A
20242024-11-30USD 0.05N/A
20252025-11-30USD -0.30N/A
Cryo-Cell International sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-08-29125.0%
Q42025-11-30-611.1%
Q12026-02-28101.3%
Q22026-05-311106.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$7.78M

-1.9%

Gross Profit

$5.92M

-2.6%

Gross Margin

76.07%

N/A

Market Cap

$32.25MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$435.82K

N/A

Employees

74

N/A

Net Income

$554.59K

+55.9%

EBITDA

$1.61M

-0.7%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$3.16M

-28.6%

Total Debt

$8.96M

-43.2%

Accounts Receivable

$6.91M

-0.3%

Inventory

$310.17K

-54.2%

Long Term Debt

$8.34M

-1.9%

Short Term Debt

$617.02K

-91.5%

Return on Assets

-4.06%

N/A

Return on Invested Capital

-0.23%

N/A

Free Cash Flow

$1.81M

+181.3%

Operating Cash Flow

$1.85M

+161.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
RMTIRockwell Medical, Inc.
$8.31+1.71%
PIIIP3 Health Partners Inc.
$9.06-1.74%
MURAMural Oncology plc
$2.04+0.00%
YI111, Inc.
$3.30-4.74%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About CCEL

What is the current price of Cryo-Cell International?

Cryo-Cell International is trading at $4.20 per share.

What is the 52-week range for Cryo-Cell International?

Over the past 52 weeks, Cryo-Cell International has traded between $2.72 and $5.01.

How much debt does Cryo-Cell International have?

As of the most recent reporting period, Cryo-Cell International reported total debt of $8.96M.

How much cash does Cryo-Cell International have on hand?

Cryo-Cell International reported $507.30K in cash and cash equivalents in its most recent financial results.

What is Cryo-Cell International’s dividend yield?

Cryo-Cell International does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services